Pfizer
PFE
3,088 hedge funds and large institutions have $170B invested in Pfizer in 2022 Q3 according to their latest regulatory filings, with 138 funds opening new positions, 1,360 increasing their positions, 1,229 reducing their positions, and 169 closing their positions.
32% more call options, than puts
Call options by funds: $2.68B | Put options by funds: $2.03B
11% more repeat investments, than reductions
Existing positions increased: 1,360 | Existing positions reduced: 1,229
0.38% more ownership
Funds ownership: 68.78% → 69.16% (+0.38%)
2% less funds holding
Funds holding: 3,160 → 3,088 (-72)
16% less capital invested
Capital invested by funds: $202B → $170B (-$32.3B)
18% less first-time investments, than exits
New positions opened: 138 | Existing positions closed: 169
38% less funds holding in top 10
Funds holding in top 10: 252 → 156 (-96)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$507M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$292M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$286M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$250M |
| 5 |
Amundi
Paris,
France
|
+$192M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$403M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$180M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$131M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$128M |
| 5 |
BlackRock
New York
|
-$123M |
PFE Hedge Fund Activity: Q3 2022 in Review
3,088 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2022, worth a combined $170B — down 16% from $202B a quarter earlier.
Sellers outnumbered buyers: 169 funds closed out of PFE and 138 opened new positions — a net loss of 31 holders — while 1,229 trimmed existing stakes and 1,360 added.
The largest buyer was Assenagon Asset Management, adding an estimated $507M. The largest seller was Wellington Management Group, cutting an estimated $403M.
- 3,088 institutional investors held Pfizer (PFE) as of Q3 2022, down from 3,160 in Q2 2022.
- Funds reported $170B of Pfizer stock for Q3 2022, down 16% quarter-over-quarter.
- 138 funds opened new Pfizer positions in Q3 2022 and 169 closed out, a net change of -31 holders.
- The largest Pfizer buyer in Q3 2022 was Assenagon Asset Management, an estimated $507M added.
- The largest Pfizer seller in Q3 2022 was Wellington Management Group, an estimated $403M sold.
Based on aggregated 13F filings for Q3 2022.